Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study

[1]  T. Chevalier,et al.  Should progression-free survival be the primary measure of efficacy for advanced NSCLC therapy? , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  J. Cuzick,et al.  Relationship between effects on time-to-disease progression and overall survival in studies of metastatic breast cancer , 2008, British Journal of Cancer.

[3]  A. D. Van den Abbeele,et al.  CT tumor volume measurement in advanced non-small-cell lung cancer: Performance characteristics of an emerging clinical tool. , 2011, Academic radiology.

[4]  E. Halpern,et al.  CT tumor measurement for therapeutic response assessment: comparison of unidimensional, bidimensional, and volumetric techniques initial observations. , 2002, Radiology.

[5]  D. DeMets,et al.  Surrogate End Points in Clinical Trials: Are We Being Misled? , 1996, Annals of Internal Medicine.

[6]  A. Jemal,et al.  Cancer Statistics, 2005 , 2005, CA: a cancer journal for clinicians.

[7]  L. Schwartz,et al.  Change in lung tumor volume as a biomarker of treatment response: a critical review of the evidence. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[8]  Chuong D. Hoang,et al.  Tumor Volume as a Potential Imaging-Based Risk-Stratification Factor in Trimodality Therapy for Locally Advanced Non-small Cell Lung Cancer , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  Kyung Soo Lee,et al.  Volume-Based Parameter of 18F-FDG PET/CT in Malignant Pleural Mesothelioma: Prediction of Therapeutic Response and Prognostic Implications , 2010, Annals of Surgical Oncology.

[10]  P. Nederlof,et al.  EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  L. Schwartz,et al.  Lung cancer: computerized quantification of tumor response--initial results. , 2006, Radiology.

[12]  G. Goldmacher,et al.  The use of tumour volumetrics to assess response to therapy in anticancer clinical trials. , 2012, British journal of clinical pharmacology.

[13]  Y. Ohe,et al.  EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: a historical comparison of patients treated before and after gefitinib approval in Japan. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  L. Schwartz,et al.  Time to tumor growth: a model end point and new metric system for oncology clinical trials. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  D. Yankelevitz,et al.  Preoperative treatment with pazopanib (GW786034), a multikinase angiogenesis inhibitor in early-stage non-small cell lung cancer (NSCLC): A proof-of-concept phase II study , 2008 .

[16]  William Pao,et al.  A Pilot Study of Volume Measurement as a Method of Tumor Response Evaluation to Aid Biomarker Development , 2010, Clinical Cancer Research.

[17]  Daniel J Sargent,et al.  Response-independent survival benefit in metastatic colorectal cancer: a comparative analysis of N9741 and AVF2107. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Andrew J Buckler,et al.  Measurement of tumor volumes improves RECIST-based response assessments in advanced lung cancer. , 2012, Translational oncology.

[19]  Geert Molenberghs,et al.  Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.

[20]  I. Sohn,et al.  Randomized phase II study of gefitinib versus erlotinib in patients with advanced non-small cell lung cancer who failed previous chemotherapy. , 2010, Lung cancer.

[21]  C. Jaffe.  Measures of response: RECIST, WHO, and new alternatives. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Tomasz Burzykowski,et al.  Is prostate-specific antigen a valid surrogate end point for survival in hormonally treated patients with metastatic prostate cancer? Joint research of the European Organisation for Research and Treatment of Cancer, the Limburgs Universitair Centrum, and AstraZeneca Pharmaceuticals. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. Buyse,et al.  Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Minita Shah,et al.  Volumetric 3D CT analysis - an early predictor of response to therapy , 2007 .

[25]  Nenad Sarapa,et al.  Evaluation of tumor-size response metrics to predict overall survival in Western and Chinese patients with first-line metastatic colorectal cancer. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.